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Cell therapy and tissue engineering hold great promise; however, current ma-
nufacturing methods constrain economic viability, especially for ‘patient-scale’ pro-
duction 
Despite significant production constraints in terms of clinical scale-up, autolo-
gous and matched allogeneic treatments continue to find considerable clinical inte-
rest due to the ability to avoid immunologic complications. In these clinical models, 
‘patient-scale’ production is the term adopted for autologous or matched allogenic 
cell therapy procedures where the size of the cell production event is necessarily 
matched to the requirements of a single therapy. 
We examine five critical issues in the successful clinical delivery of patient-scale 
cell therapy and evaluate potential solutions based on the use of advanced bioreac-
tors. The high cost of cell therapy production protocols is considered in the context 
of automation where electronic instrumentation linked to disposable bioreactors 
creates production efficiencies. The adoption of such bioreactor-based platforms 
combined with flexible instrumentation programming allows cell production cen-
ters to produce cell therapy treatments for diverse clinical conditions. Furthermore, 
the incorporation of biosensors as essential monitoring aids in the bioreactor en-
vironment provides the opportunity for pre-validated software to effect discrete 
process changes to accommodate inherent variability in cell performance on a pa-
tient-by-patient basis. The use of such electronic protocols and biological feedback 
implicitly drives the availability of comprehensive electronic batch records, which 
enhance GMP traceability and support the complex clinical logistics inherent in 
autologous processes. 
Through the use of automated processes delivered by bioreactor-based produc-
tion platforms, we propose new clinical models for patient-scale cell production that 
address today’s demanding expectations for reliable biological performance, effecti-
ve GMP logistics, and economic viability. 
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